外科理论与实践

外科理论与实践 >

2020 , Vol. 25 >Issue 01: 79 - 82

DOI: https://doi.org/10.16139/j.1007-9610.2020.01.018

综述

多发性大动脉炎治疗的新进展

展开
  • 海军军医大学附属长海医院血管外科,上海 200433

收稿日期: 2019-04-30

  网络出版日期: 2020-02-25

基金资助

国家自然科学基金(81770482)

收起

New advance in treatment of Takayasu arteritis

Expand

Received date: 2019-04-30

  Online published: 2020-02-25

Fold

本文引用格式

韩同磊, 孙羽东, 魏小龙, 赵志青, 景在平 . 多发性大动脉炎治疗的新进展[J]. 外科理论与实践, 2020 , 25(01) : 79 -82 . DOI: 10.16139/j.1007-9610.2020.01.018

参考文献

[1] Mirouse A, Biard L, Comarmond C, et al. Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients[J]. J Autoimmun, 2019, 96(1):35-39.
[2] Xiao Y, Zhou J, Wei X, et al. Outcomes of different treatments on Takayasu's arteritis[J]. J Thorac Dis, 2016, 8(9):2495-2503.
[3] De Souza AW, De Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis[J]. J Autoimmun, 2014, 48(2):79-83.
[4] Janarthanan M, Rathinasamy J. Aortic calcification in longstanding, undiagnosed Takayasu arteritis[J]. Lancet, 2018, 392(10151):950.
[5] Gomez L, Chaumet-Riffaud P, Noel N, et al. Effect of CRP value on F-FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2018, 45(4):575-581.
[6] Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients[J]. Circulation, 2017, 136(12):1114-1122.
[7] Park SJ, Kim HJ, Park H, et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study[J]. Int J Cardiol, 2017, 235(5):100-104.
[8] Gudbrandsson B, Molberg O, Garen T, et al. Prevalence, incidence, and disease characteristics of Takayasu arteritis by ethnic background: data from a large, population-based cohort resident in southern norway[J]. Arthritis Care Res (Hoboken), 2017, 69(2):278-285.
[9] Hong C, Zeng T, Zhao J, et al. Takayasu's arteritis misdiagnosed as mediastinal malignant lymphoma: a case report and review of the literature[J]. J Thorac Dis, 2014, 6(6):E115-E119.
[10] Aeschlimann FA, Barra L, Alsolaimani R, et al. Presentation and disease course of childhood-onset versus adult-onset Takayasu arteritis[J]. Arthritis Rheumatol, 2019, 71(2):315-323.
[11] Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in japan: age and sex specificity[J]. Circulation, 2015, 132(18):1701-1709.
[12] Mwipatayi BP, Jeffery PC, Beningfield SJ, et al. Takayasu arteritis: clinical features and management: report of 272 cases[J]. ANZ J Surg, 2005, 75(3):110-117.
[13] Tyagi S, Bansal A, Gupta MD, et al. Endovascular ma-nagement of acute aortic dissection in Takayasu arteritis[J]. JACC Cardiovasc Interv, 2018, 11(12):e99-e101.
[14] Park EH, Lee EY, Lee YJ, et al. Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study[J]. Rheumatol Int, 2018, 38(12):2233-2242.
[15] Goel R, Sathish KT, Danda D. Childhood-onset Takayasu arteritis (c-ta): current and future drug therapy[J]. Paediatr Drugs, 2019, 21(2):81-93.
[16] Misra DP, Wakhlu A, Agarwal V, et al. Recent advances in the management of Takayasu arteritis[J]. Int J Rheum Dis, 2019, 22(1):60-68.
[17] Samson M, Espigol-Frigole G, Terrades-Garcia N, et al. Biological treatments in giant cell arteritis & Takayasu arteritis[J]. Eur J Intern Med, 2018, 50(4):12-19.
[18] Decker P, Olivier P, Risse J, et al. Tocilizumab and refractory Takayasu disease: Four case reports and syste-matic review[J]. Autoimmun Rev, 2018, 17(4):353-360.
[19] Sanchez-Alvarez C, Koster M, Duarte-García A, et al. Disease progression of Takayasu arteritis in two patients treated with tocilizumab[J]. Ann Rheum Dis, 2018-12-08[Epub ahead of print].
[20] Kong X, Zhang X, Lv P, et al. Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide[J]. Int J Cardiol, 2018, 266(9):222-228.
[21] Mekinian A, Resche-Rigon M, Comarmond C, et al. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients[J]. J Autoimmun, 2018, 91(7):55-60.
[22] Salvarani C, Hatemi G. Management of large-vessel vasculitis[J]. Curr Opin Rheumatol, 2019, 31(1):25-31.
[23] Muratore F, Pipitone N, Salvarani C. Standard and biolo-gical treatment in large vessel vasculitis: guidelines and current approaches[J]. Expert Rev Clin Immunol, 2017, 13(4):345-360.
[24] Ferfar Y, Mirault T, Desbois AC, et al. Biotherapies in large vessel vasculitis[J]. Autoimmun Rev, 2016, 15(6):544-551.
[25] De Franciscis S, Serra R, Luongo A, et al. The management of Takayasu's arteritis: personal experience[J]. Ann Vasc Surg, 2007, 21(6):754-760.
[26] Keser G, Aksu K. What is new in management of Takayasu arteritis?[J]. Presse Med, 2017, 46(7-8 Pt 2):e229-e235.
[27] Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients[J]. Circulation, 2015, 132(18):1693-1700.
[28] Novikov PI, Smitienko IO, Sokolova MV, et al. Certolizumab pegol in the treatment of Takayasu arteritis[J]. Rheumatology (Oxford), 2018, 57(12):2101-2105.
[29] Gudbrandsson B, Molberg O, Palm O. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study[J]. Arthritis Res Ther, 2017, 19(1):99.
[30] Schmidt J, Kermani TA, Bacani AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup[J]. Arthritis Care Res (Hoboken), 2012, 64(7):1079-1083.
[31] Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up[J]. Ann Rheum Dis, 2008, 67(11):1567-1569.
[32] Lee YH, Song GG. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis[J]. Ann Rheum Dis, 2019, 78(1):e9.
[33] Loricera J, Blanco R, Hernandez JL, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review[J]. Clin Exp Rheumatol, 2016, 34(3 Suppl 97):S44-S53.
[34] Risse J, Mandry D, Settembre N, et al. Dramatic response to tocilizumab before emergency surgery in severe active Takayasu disease[J]. Circ Cardiovasc Imaging, 2016, 9(7).pii: e004819.
[35] Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis[J]. Arthritis Rheum, 2004, 50(4):1332-1337.
[36] Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis[J]. Arthritis Rheumatol, 2017, 69(4):846-853.
[37] Li J, Zhu M, Li M, et al. Cause of death in Chinese Takayasu arteritis patients[J]. Medicine (Baltimore), 2016, 95(27):e4069.
[38] Lee BB. Simultaneous multiple bypass for Takayasu arteritis[J]. Eur J Vasc Endovasc Surg, 2018, 56(6):910.
[39] Chen ZG, Chen YX, Diao YP, et al. Simultaneous multi-supra-aortic artery bypass successfully implemented in 17 patients with type Ⅰ Takayasu arteritis[J]. Eur J Vasc Endovasc Surg, 2018, 56(6):903-909.
[40] 冯睿, 魏小龙, 赵志青, 等. 采用单条大隐静脉行腹主动脉-双侧肾动脉旁路术治疗大动脉炎性肾动脉狭窄[J]. 外科理论与实践, 2011, 16(2):151-154.
[41] Kim YW, Kim DI, Park YJ, et al. Surgical bypass vs. endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis[J]. J Vasc Surg, 2012, 55(3):693-700.
[42] Mason JC. Surgical intervention and its role in Takayasu arteritis[J]. Best Pract Res Clin Rheumatol, 2018, 32(1):112-124.
[43] Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients[J]. Mayo Clin Proc, 2013, 88(8):822-830.
[44] Che W, Xiong H, Jiang X, et al. Stenting for middle aortic syndrome caused by Takayasu arteritis-immediate and long-term outcomes[J]. Catheter Cardiovasc Interv, 2018, 91(S1):623-631.
[45] Hadjadj J, Canaud G, Mirault T, et al. mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G[J]. Rheumatology (Oxford), 2018, 57(6):1011-1020.
[46] Saleh HM, Gabr AK, Tawfik MM, et al. Prospective, randomized study of cutting balloon angioplasty versus conventional balloon angioplasty for the treatment of hemodialysis access stenoses[J]. J Vasc Surg, 2014, 60(3):735-740.
[47] Gumus B, Cevik H, Vuran C, et al. Cutting balloon angioplasty of bilateral renal artery stenosis due to Takayasu arteritis in a 5-year-old child with midterm follow-up[J]. Cardiovasc Intervent Radiol, 2010, 33(2):394-397.
[48] Tyagi S, Sarkar PG, Gupta MD, et al. Restoration of vision by endovascular revascularization in Takayasu arteritis: A case series[J]. J Cardiol Cases, 2018, 18(4):123-127.
Options
文章导航

/

〈 〉